Title:
METHODS FOR INDUCING SUSTAINED IMMUNE RESPONSE
Document Type and Number:
WIPO Patent Application WO2002092018
Kind Code:
A3
Abstract:
A method for promoting a sustained increased level of T-cell production in immunocompromised subjects in which method enkephalin peptides are administered according to an intermittent dose schedule. In particular, the method involves treatment of immunocompromised patients which includes the administration of enkephalin, either alone or in conjunction with other therapies, in an initial dosage regimen, with periodic booster dosages of enkephalin as necessary to maintain sustained immune system response.
Inventors:
PLOTNIKOFF NICHOLAS P (US)
Application Number:
PCT/US2002/018529
Publication Date:
December 11, 2003
Filing Date:
May 16, 2002
Export Citation:
Assignee:
PLOTNIKOFF NICHOLAS P (US)
International Classes:
A61K38/33; A61K38/00; A61K38/12; (IPC1-7): A61K38/00; A01N25/00; C07K7/00
Foreign References:
| US4537878A | 1985-08-27 | |||
| US4801614A | 1989-01-31 |
Other References:
DATABASE MEDLINE [online] ZHONG ET AL.: "Augmentation of TNF-alpha production, NK cell activity and IL-12 p35 mRNA expression by methionine enkephalin", XP002964175, Database accession no. 98445852
DATABASE MEDLINE [online] YANG ET AL.: "Influence of methionine-enkephalin on interleukin-2 production and interleukin-2 receptor expression", XP002964176, Database accession no. 92286174
DATABASE MEDLINE [online] YANG ET AL.: "Influence of methionine-enkephalin on interleukin-2 production and interleukin-2 receptor expression", XP002964176, Database accession no. 92286174
Download PDF:
Previous Patent: HUMAN ANTIPNEUMOCOCCAL ANTIBODIES FROM NON-HUMAN ANIMALS
Next Patent: HALOGENATED ANTITUBERCULOSIS AGENTS
Next Patent: HALOGENATED ANTITUBERCULOSIS AGENTS